Oxford Cannabinoid Tech.Holdings Appointment of General Counsel & Notice of Results (6819M)

TIDMOCTP

RNS Number : 6819M

Oxford Cannabinoid Tech.Holdings

16 January 2023

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Appointment of General Counsel & Company Secretary

Notice of Results

& Analyst and Investor Presentations

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market, is pleased to announce the appointment of Robin ("Rob") Bennett as General Counsel and Company Secretary. Rob joined the Company in December 2022 as General Counsel and was appointed Company Secretary on 12 January 2023.

Rob brings a wealth of experience and expertise to the Company from his role as General Counsel and Company Secretary at Bestway Wholesale (formerly Costcutter Supermarkets Group). He has over 15 years of UK and international experience across multiple sectors, including retail, fast-moving consumer goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and compliance has been gained through working with SMEs and quoted companies such as SABMiller plc. He has been recognised for his work by being listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The Lawyer Awards in 2021.

Clarissa Sowemimo-Coker, interim CEO said: "We are delighted to welcome Rob to OCTP. His experience in the UK and internationally is hugely beneficial to us, as is his expertise in M&A. He is quickly becoming a valued member of our team."

Notice of Results & Analyst and Investor Presentations

The Company intends to announce results for the six-month period ended 31 October 2022 on Monday 23 January 2023.

Analyst Briefing, 09.30, Monday 23 January 2023

A briefing for analysts will be held at 09.30 GMT on the day of the results.

Analysts interested in attending should contact Walbrook PR by emailing [e-mail] or by calling 020 7933 8780.

Investor Presentation, 16.30, Monday 23 January 2023

A live online presentation via the Investor Meet Company platform will also be held at 16.30 GMT on Monday 23 January 2023, which is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and add to meet Oxford Cannabinoid Technologies Holdings plc via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Investors who already follow OCTP on the Investor Meet Company platform will automatically receive an invitation to the event.

The Directors of the Company accept responsibility for the content of this announcement.

 
  Enquiries: 
    Oxford Cannabinoid Technologies Holdings    [phone] 
     plc                                         [e-mail] 
     Clarissa Sowemimo-Coker (Interim CEO) 
    Cairn Financial Advisers LLP 
     Emily Staples                               [phone] 
     Jo Turner                                   [phone] 
    Axis Capital Markets Limited 
     Kamran Hussain                              [phone] 
     Richard Hutchison 
 
     finnCap Ltd 
     Geoff Nash/Fergus Sullivan                  [phone] 
     Nigel Birks (ECM) 
 
     Walbrook PR Limited                         [phone] 
     Paul Vann/Nick Rome                         [phone] 
                                                 [e-mail] 
 
 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of a pharmaceutical Group developing prescription cannabinoid medicines targeting the U$ multi-billion global pain market.

OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with Phase 1 clinical trials, aimed at demonstrating safety and tolerability, due to commence in the near term. Trial results are expected in Q2 2023. The global market for CIPN alone was valued at US$1.61bn in 2020 and is forecast to reach US$2.37bn by the year 2027.

OCTP's drug development pipeline, comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of over 400 derivatives and intellectual property rights including 14 patent families and associated research data.

OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGPUPPGUPWGUW

(END) Dow Jones Newswires

January 16, 2023 02:00 ET (07:00 GMT)